Kevin Gregg

1.8k total citations
22 papers, 352 citations indexed

About

Kevin Gregg is a scholar working on Epidemiology, Infectious Diseases and Surgery. According to data from OpenAlex, Kevin Gregg has authored 22 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 11 papers in Infectious Diseases and 5 papers in Surgery. Recurrent topics in Kevin Gregg's work include Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Cytomegalovirus and herpesvirus research (4 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Kevin Gregg is often cited by papers focused on Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Cytomegalovirus and herpesvirus research (4 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Kevin Gregg collaborates with scholars based in United States, Portugal and Italy. Kevin Gregg's co-authors include Carol A. Kauffman, Daniel Kaul, James Riddell, William A. Werbel, Douglas E. Schaubel, Bernard L. Marini, Jerod Nagel, Katherine Baumgarten, Roseanne Ressner and Adrian M. Zelazny and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and CHEST Journal.

In The Last Decade

Kevin Gregg

21 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Gregg United States 12 190 178 57 54 46 22 352
Jessica Mencarini Italy 10 110 0.6× 191 1.1× 28 0.5× 65 1.2× 20 0.4× 27 285
Julien Coussement Belgium 12 224 1.2× 105 0.6× 55 1.0× 63 1.2× 18 0.4× 22 441
Keitaro Nakamoto Japan 13 182 1.0× 113 0.6× 33 0.6× 65 1.2× 117 2.5× 63 557
Lara Beth Gadkowski United States 7 205 1.1× 178 1.0× 19 0.3× 97 1.8× 8 0.2× 8 393
Kamonwan Jutivorakool Thailand 10 377 2.0× 260 1.5× 70 1.2× 50 0.9× 179 3.9× 21 602
Anthony I. Sahyoun United States 7 102 0.5× 92 0.5× 32 0.6× 92 1.7× 35 0.8× 12 323
H. Coignard France 7 189 1.0× 153 0.9× 19 0.3× 126 2.3× 23 0.5× 13 349
Matthias Hoffmann Switzerland 5 146 0.8× 80 0.4× 65 1.1× 51 0.9× 27 0.6× 9 313
S. Kim Jacobson United Kingdom 9 275 1.4× 111 0.6× 37 0.6× 126 2.3× 45 1.0× 14 589
Almerico Marruchella Italy 9 168 0.9× 125 0.7× 36 0.6× 63 1.2× 40 0.9× 22 401

Countries citing papers authored by Kevin Gregg

Since Specialization
Citations

This map shows the geographic impact of Kevin Gregg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Gregg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Gregg more than expected).

Fields of papers citing papers by Kevin Gregg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Gregg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Gregg. The network helps show where Kevin Gregg may publish in the future.

Co-authorship network of co-authors of Kevin Gregg

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Gregg. A scholar is included among the top collaborators of Kevin Gregg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Gregg. Kevin Gregg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weinstein, Edward A., Roger Paredes, Annie Gardner, et al.. (2025). Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. The Lancet Infectious Diseases. 25(11). 1243–1253. 3 indexed citations
2.
Aitken, Samuel L, Ji Hoon Baang, Daniel Kaul, et al.. (2023). Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series. Open Forum Infectious Diseases. 10(4). ofad189–ofad189. 17 indexed citations
3.
4.
Kaul, Daniel, Kevin Gregg, Jessica R. Golbus, et al.. (2023). Cytomegalovirus infection is associated with impaired myocardial flow reserve after heart transplantation. The Journal of Heart and Lung Transplantation. 43(3). 432–441. 3 indexed citations
5.
Frame, David, Thomas Braun, Mary Maliarik, et al.. (2022). Defibrotide Therapy for SARS-CoV-2 ARDS. CHEST Journal. 162(2). 346–355. 11 indexed citations
6.
Marini, Bernard L., et al.. (2022). Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. Journal of the National Comprehensive Cancer Network. 20(3). 245–252. 12 indexed citations
7.
Bell, J.N.B., Oryan Henig, Kara L. Sawaya, et al.. (2022). Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients. SHILAP Revista de lepidopterología. 2(S1). s72–s73. 2 indexed citations
8.
Conrady, Christopher D., J. Lisa, Kevin Gregg, & Rajesh C. Rao. (2021). Coronavirus-19-Associated Retinopathy. Ocular Immunology and Inflammation. 29(4). 675–676. 11 indexed citations
9.
10.
Mullane, Kathleen M., Drew J. Winston, Ajay K. Nooka, et al.. (2018). A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis ofClostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases. 68(2). 196–203. 42 indexed citations
11.
Patel, Twisha S, Hannah Imlay, Daniel Kaul, Linda J. Stuckey, & Kevin Gregg. (2017). Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant Cytomegalovirus Infection in Lung Transplant Recipients. Open Forum Infectious Diseases. 4(suppl_1). S730–S730. 7 indexed citations
12.
Marini, Bernard L., et al.. (2015). Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. Supportive Care in Cancer. 23(8). 2287–2295. 13 indexed citations
13.
Werbel, William A., et al.. (2015). Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transplant Infectious Disease. 17(4). 551–557. 36 indexed citations
14.
Rosen, Lindsey B., Roseanne Ressner, Kevin Gregg, et al.. (2014). Nocardia-Induced Granulocyte Macrophage Colony-Stimulating Factor Is Neutralized by Autoantibodies in Disseminated/Extrapulmonary Nocardiosis. Clinical Infectious Diseases. 60(7). 1017–1025. 63 indexed citations
15.
Hammoud, Maya M., et al.. (2014). Disseminated Nocardia paucivorans infection in an immunocompetent host. Infection. 42(5). 917–920. 12 indexed citations
16.
Gregg, Kevin, Morgan Hakki, & Daniel Kaul. (2014). UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease. Transplant Infectious Disease. 16(2). 320–323. 5 indexed citations
17.
18.
Gregg, Kevin, Burc Barin, David Pitrak, Charulata Ramaprasad, & Kenneth Pursell. (2013). Acquired hypogammaglobulinemia in HIV‐positive subjects after liver transplantation. Transplant Infectious Disease. 15(6). 581–587. 2 indexed citations
19.
Reid, Gail, Shirish Huprikar, Gopi Patel, et al.. (2013). A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transplant Infectious Disease. 15(5). 487–492. 21 indexed citations
20.
Song, Jie, Suncica Volkov, Christopher R. Shea, et al.. (2008). Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases. Journal of Cutaneous Pathology. 36(s1). 31–34. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Mencarini Breakdown of academic impact, for papers by Julien Coussement Breakdown of academic impact, for papers by Keitaro Nakamoto Breakdown of academic impact, for papers by Lara Beth Gadkowski Breakdown of academic impact, for papers by Kamonwan Jutivorakool Breakdown of academic impact, for papers by Anthony I. Sahyoun Breakdown of academic impact, for papers by H. Coignard Breakdown of academic impact, for papers by Matthias Hoffmann Breakdown of academic impact, for papers by S. Kim Jacobson Breakdown of academic impact, for papers by Almerico Marruchella
Rankless by CCL
2026